Michael Luggen is a Rheumatology/Immunology physician affiliated with University of Cincinnati. OpenAlex indexes 60 publications with 5,065 citations (h-index 27).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
311 Straight St
Cincinnati, OH 452191018
Telephone
513-559-2898Registry record last updated 9 Aug 2017.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53.1%TNF inhibitor37.4%Infliximab87%Enbrel Sureclick7%Humira(Cf) Pen3%Simponi1%Humira(Cf)1%Humira1%Cimzia (2 Pack)1%Part D + Part B<11 patientsFolate Analog Metabolic Inhibitor7.8%Methotrexate97%Methotrexate Sodium3%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
14.5%Corticosteroid10.9%Prednisone100%Part D≥123 patientsAminosalicylate2%Sulfasalazine Dr56%Sulfasalazine44%Part D≥22 patients+ 2 more classes in this area
Nervous system
12.1%Opioid Agonist5.1%Oxycodone-Acetaminophen65%Tramadol Hcl23%Oxycodone Hcl12%Part D<11 patientsGabapentinoids3.7%Gabapentin77%Pregabalin23%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1990–1990 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial
Arthritis Research & Therapy
2025 - Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
Annals of the Rheumatic Diseases
2024 - Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
Modern Rheumatology Journal
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Alberto Espay, MD
University of Cincinnati
Eva Mistry, MD
University of Cincinnati
Brett Kissela, MD
University of Cincinnati
Evangelia Galani Kranias
University of Cincinnati
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”